FZD9 and cancer: The identification of Fzd9 as a key Myc-driven tumorigenic effector is particularly relevant in view of the fact that, even if Myc is one of the “most wanted” cancer targets, several direct, and indirect Myc inhibition strategies have failed because of lack of efficacy and high toxicity derived from low specificity (Whitfield et al, 2017).